...
首页> 外文期刊>Infection and Drug Resistance >Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia
【24h】

Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia

机译:黎巴嫩和沙特阿拉伯住院患者耐甲氧西林金黄色葡萄球菌肺炎的负担

获取原文

摘要

Objectives: The objective of this study is to describe the real-world treatment patterns and burden of suspected or confirmed methicillin-resistant Staphylococcus aureus (MRSA) pneumonia in Saudi Arabia and Lebanon. Methods: A retrospective chart review study evaluated 2011–2012 data from hospitals in Saudi Arabia and Lebanon. Patients were included if they had been discharged with a diagnosis of MRSA pneumonia, which was culture proven or suspected based on clinical criteria. Hospital data were abstracted for a random sample of patients to capture demographics (eg, age and comorbidities), treatment patterns (eg, timing and use of antimicrobials), hospital resource utilization (eg, length of stay), and clinical outcomes (eg, clinical status at discharge and mortality). Descriptive results were reported using frequencies or proportions for categorical variables and mean and standard deviation for continuous variables. Results: Chart-level data were collected for 93 patients with MRSA pneumonia, 50 in Saudi Arabia and 43 in Lebanon. The average age of the patients was 56?years, and 60% were male. The most common comorbidities were diabetes (39%), congestive heart failure (30%), coronary artery disease (29%), and chronic obstructive pulmonary disease (28%). Patients most frequently had positive cultures from pulmonary (87%) and blood (27%) samples. All isolates were sensitive to vancomycin, teicoplanin, and linezolid, and only one-third of the isolates tested were sensitive to ciprofloxacin. Beta-lactams (inactive therapy for MRSA) were prescribed 21% of the time across all lines of therapy, with 42% of patients receiving first-line beta-lactams. Fifteen percent of patients did not receive any antibiotics that were considered to be MRSA active. The mean hospital length of stay was 32?days, and in-hospital mortality was 30%. Conclusion: The treatment for MRSA pneumonia in Saudi Arabia and Lebanon may be suboptimal with inactive therapy prescribed a substantial proportion of the time. The information gathered from this Middle East sample provides important perspectives on the current treatment patterns.
机译:目的:本研究的目的是描述沙特阿拉伯和黎巴嫩的疑似或确诊的耐甲氧西林金黄色葡萄球菌(MRSA)肺炎的现实治疗模式和负担。方法:一项回顾性图表审查研究评估了2011-2012年沙特阿拉伯和黎巴嫩医院的数据。如果患者出院时已诊断出MRSA肺炎,则将其包括在内,这是根据临床标准经培养证实或怀疑的。从患者的随机样本中提取医院数据,以收集人口统计数据(例如年龄和合并症),治疗模式(例如抗菌药物的时间和使用),医院资源利用(例如住院时间)和临床结果(例如出院时的临床状况和死亡率)。使用分类变量的频率或比例以及连续变量的均值和标准差报告描述性结果。结果:收集了93例MRSA肺炎患者,沙特阿拉伯50例和黎巴嫩43例的图表级数据。患者的平均年龄为56岁,男性为60%。最常见的合并症是糖尿病(39%),充血性心力衰竭(30%),冠状动脉疾病(29%)和慢性阻塞性肺疾病(28%)。患者最常见的是肺部(87%)和血液(27%)样本中的阳性培养物。所有分离株均对万古霉素,替考拉宁和利奈唑胺敏感,仅三分之一的分离株对环丙沙星敏感。在所有疗法中,有21%的时间处方了β-内酰胺类药物(MRSA无效治疗),其中42%的患者接受一线β-内酰胺类药物。 15%的患者未接受任何被认为具有MRSA活性的抗生素。平均住院时间为32天,住院死亡率为30%。结论:沙特阿拉伯和黎巴嫩对MRSA肺炎的治疗可能不理想,并且在相当长的时间内开了非活性疗法。从中东样本中收集的信息为当前治疗模式提供了重要的观点。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号